公共场所卫生监督监测结果分析

为掌握南关区公共场所的卫生状况，发现存在的问题，制定相应的预防措施，我们于2004年7～9月份对重点公共场所进行了卫生监督检查和采样监测。     

无血液培养基分离嗜血杆菌的方法学研究

目的评价自制不加血液的培养基和传统的羊血巧克力培养基分离嗜血杆菌的效果。方法将流感嗜血杆菌ATCC10211接种于无血液培养基和传统培养基上,计算和比较两种培养基上嗜血杆菌的平均生长指数,并用此两种培养基对225份临床痰标本进行嗜血杆菌的分离,比较两种培养基上嗜血杆菌的分离率。结果无血液培养基与传统巧克力培养基的平均生长指数分别为11.06、8.05,225份痰标本中嗜血杆菌的分离率分别为20%、11.6%,两者有显著性差异(P<0.01)。结论无血液培养基分离嗜血杆菌的方法简便、实用、效果较好,有应用推广价值。     

乙型肝炎免疫球蛋白聚氰基丙烯酸正丁酯纳米粒抑制HBsAg、HBV DNA分泌的体外实验

Objective To investigate the inhibitive activities of hepatitis B immunoglobulin(HBIG)poly(butylcynaoacrylate)nanoparticles(HBIG-PBCA-NP)to hepatitis B surface antigen(HBsAg)and hepatitis B virus(HBV)DNA secretions using HBV infected cell model in vitro.Methods HepG 2.2.15 cells were cultured with media containing HBIG-PBCA-NP or HBIG for several days,or cultured with HBIG-PBC-NP and HBIG for 2 days and without HBIG-PBCA-NP and HBIG from day 3.The supernatants at different time points were collected for quantitative detection of HBsAg and HBV DNA.The comparisons between groups were done by variance analysis.Resalts Secretions of HBsAg and HBV DNA in supernatants of HepG2.2.15 cultured with 0.1-10.0 IU/mL of HBIG-PBCA-NP and HBIG were inhibited significantly compared with control group.HBsAg titers and HBV DNA levels in supernatants of HBIG-PBCA-NP group and HBIG group cultured with media without HBIG-PBCA-NP and HBIG kept decreasing at day 5 and 7,then rebounded at day 9 and 11.HBsAg titera in supernatants of 0.1,1.0,5.0 IU/mL HBIG-PBCA-NP group were all significantly different from those in HBIG group at day 9[(31.31±1.98)μg/L vs(40.62±2.99)μg/L,(23.79±1.31)μg/L vs(36.51±2.12)μg/L,(19.91±1.74)μg/L vs(33.03±1.65)μg/L;F=412.24,P＜0.01].Couclusion HBIG-PBCA-NP can inhibit secretions of HgsAg and HBV DNA in vitro,which is more effective than HBIG.     

乙型肝炎免疫球蛋白聚氰基丙烯酸正丁酯纳米粒抑制HBsAg、HBV DNA分泌的体外实验

Objective To investigate the inhibitive activities of hepatitis B immunoglobulin(HBIG)poly(butylcynaoacrylate)nanoparticles(HBIG-PBCA-NP)to hepatitis B surface antigen(HBsAg)and hepatitis B virus(HBV)DNA secretions using HBV infected cell model in vitro.Methods HepG 2.2.15 cells were cultured with media containing HBIG-PBCA-NP or HBIG for several days,or cultured with HBIG-PBC-NP and HBIG for 2 days and without HBIG-PBCA-NP and HBIG from day 3.The supernatants at different time points were collected for quantitative detection of HBsAg and HBV DNA.The comparisons between groups were done by variance analysis.Resalts Secretions of HBsAg and HBV DNA in supernatants of HepG2.2.15 cultured with 0.1-10.0 IU/mL of HBIG-PBCA-NP and HBIG were inhibited significantly compared with control group.HBsAg titers and HBV DNA levels in supernatants of HBIG-PBCA-NP group and HBIG group cultured with media without HBIG-PBCA-NP and HBIG kept decreasing at day 5 and 7,then rebounded at day 9 and 11.HBsAg titera in supernatants of 0.1,1.0,5.0 IU/mL HBIG-PBCA-NP group were all significantly different from those in HBIG group at day 9[(31.31±1.98)μg/L vs(40.62±2.99)μg/L,(23.79±1.31)μg/L vs(36.51±2.12)μg/L,(19.91±1.74)μg/L vs(33.03±1.65)μg/L;F=412.24,P＜0.01].Couclusion HBIG-PBCA-NP can inhibit secretions of HgsAg and HBV DNA in vitro,which is more effective than HBIG.     

联合检测超敏C-反应蛋白与心型脂肪酸结合蛋白在总胆固醇正常的冠心病诊断中的应用

目的探讨联合检测超敏C-反应蛋白（hs-CRP）和心型脂肪酸结合蛋白（h-FABP）对总胆固醇正常的冠心病（CHD）的诊断价值。方法对50例正常对照者（对照组）和130例CHD患者（CHD组）血清中hs-CRP和h-FABP进行测定。结果总胆固醇正常、边缘性增高和升高的CHD患者血清中hs-CRP和h-FABP均显著高于正常对照组（P〈0．01）。联合应用hs-CRP和h-FABP两种标志物判别，对总胆固醇正常的CHD患者诊断阳性率为90．0％，分别高于单独应用hs-CRP的75．0％和h-FABP的32．5％。结论联合检测hs-CRP和h-FABP，既能提高预测发生CHD的危险性，也可提高早期诊断CHD和心肌损伤的准确性。     

电化学发光法HBsAg定量分析最适稀释度及其与HBV-DNA含量关系的探讨

目的:探讨电化学发光免疫分析法(ECLIA)常见血清学模式HBsAg定量分析最适稀释度及其与HBV-DNA含量的关系。方法:采用正常混合血清倍比稀释HBsAg(+)/HBeAg(+)/HBcAb(+)、HBsAg(+)/HBeAb(+)/HBcAb(+)和HBsAg(+)/HBcAb(+)三种模式血清,ECLIA夹心法定量测定原倍及稀释血清HBsAg的浓度,荧光定量PCR测定其HBV-DNA含量(结果以对数值表示)。结果:HBsAg阳性的三种血清学模式血清最适稀释度不同,HBsAg(+)/HBeAg(+)/HBcAb(+)模式存在HD-HOOK效应,其最适稀释度为1∶32,HBsAg测定结果与HBV-DNA含量分析无显著性相关(r=0.235,P>0.05)。HBsAg(+)/HBeAb(+)/HBcAb(+)和HBsAg(+)/HBcAb(+)模式原倍血清HBsAg测定值最高,不需进行稀释,HBsAg测定结果与HBV-DNA定量分析呈正相关(r分别为0.982,0.968;P均<0.01)。结论:ECLIA法定量测定HBsAg(+)/HBeAg(+)/HBcAb(+)模式血清中HbsAg时,应参照HBV-DNA含量分析,对其血清进行预稀释,同时测定原倍和1∶32稀释血清HBsAg含量。而HBsAg(+)/HBeAb(+)/HBcAb(+)和HBsAg(+)/HBcAb(+)模式,不需进行预稀释,其血清HBsAg结果与HBV-DNA含量变化一致。     

铜绿假单胞菌对耐喹诺酮药物质粒基因的研究

目的：探讨铜绿假单胞菌对喹诺酮类药物的耐药质粒与周围共生菌耐药质粒染色体相互转移的关系。方法收集深圳市第七人民医院2011年1月～2013年12月481份各种样品培养出的铜绿假单胞菌31例,药敏实验结果对喹诺酮耐药的15例为研究对象,运用质粒转化、提取实验证实其耐药质粒的存在,PCR扩增、基因序列分析,与周围共生菌耐药质粒的基因序列比对。结果铜绿假单胞菌耐药株的耐药质粒与周围共生菌质粒发现有相同基因序列（χ2检验,χ2＝1.207,P＜0.01）。结论耐药质粒能在不同种属细菌之间传递。     

人参皂苷酸降解物细胞免疫调节作用的实验研究

目的探讨人参皂苷酸降解物对机体的细胞免疫调节功效。方法选用近交系雄性BALB/C小鼠随机分成高、中、低3个剂量组和1个阴性对照组,每组12只。实验组分别给予0.05、0.50、1.50 g/kg体重的人参皂苷酸降解物,连续给药60 d后测定足跖肿胀度和淋巴细胞转化程度。并与对照组进行对比。结果人参皂苷酸降解物能增强小鼠的迟发型变态反应,足跖肿胀度提高到0.85 mm;能提高ConA诱导的小鼠脾淋巴细胞转化能力,OD差值达到0.175。结论人参皂苷酸降解物具有增强细胞免疫调节作用。     

糖尿病并发感染37例临床分析

感染是糖尿病常见并发症之一.自胰岛素和抗生素问世以来,糖尿病并发感染的死亡率已有明显下降,但对其危害的严重性仍须认真对待.本文就我院1993年至1997年5年间住院的糖尿病患者并发感染的情况加以总结和分析.